Browsing by Author "Vial, P."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children
    (2008) Abarca, K.; Ibánez, I.; Perret Pérez, Cecilia; Vial, P.; Zinsou, J. A.
    Objectives: To compare the immunogenicity, safety, and interchangeability of two pediatric hepatitis A vaccines, Avaxim 80U-Pediatric® and Havrix 720®, in Chilean children. Methods: In this randomized trial, 332 hepatitis A virus (HAV) seronegative children from 1 to 15 years of age received two doses of Avaxim, two doses of Havrix, or Havrix followed by Avaxim, 6 months apart. Anti-HAV antibody titers were measured before and 14 days after the first dose of vaccine, and before and 28 days after the second dose of vaccine. Immediate reactions were monitored; reactogenicity was evaluated from parental reports. Results: Seroconversion rates after the first vaccination were 99.4% and 100% for Avaxim and Havrix, respectively. Anti-HAV geometric mean concentrations (GMCs) were 138 mIU/ml for Havrix (95% confidence interval (CI): 120; 159) and 311 mIU/ml for Avaxim (95% CI: 274; 353). GMCs increased to 4008 mIU/ml after two doses of Havrix, 8537 mIU/ml following two doses of Avaxim, and 7144 mIU/ml in children who received Havrix with Avaxim as the second dose. Following the first injection, 36% of subjects given Avaxim and 44% given Havrix reported local reactions; 38% of subjects in the Avaxim group and 40% in the Havrix group reported systemic reactions related to vaccination. Solicited reactions were less frequent after the second dose of Avaxim or Havrix, occurring in 27% to 37% of subjects. Conclusions: No significant difference in seroconversion rates was seen 14 days after a single dose of vaccine. A two-dose schedule with either vaccine or with Havrix/Avaxim provided a strong booster response. Both vaccines were well tolerated and can be recommended for routine vaccination of Chilean children. Avaxim 80 may be used to complete a vaccine schedule begun with Havrix 720. © 2007 International Society for Infectious Diseases.
  • Thumbnail Image
    Item
    Molecular method for the detection of Andes hantavirus infection: validation for clinical diagnostics
    (2016) Vial, C.; Martinez, C.; Rios, S.; Martinez, J.; Vial, P.; Ferrés Garrido, Marcela Viviana; Rivera, J.; Perez, R.; Valdivieso, F.
  • Thumbnail Image
    Item
    Yellow fever vaccination for chilean tourists visiting Brazil. Practical considerations
    (2018) Weitzel, T.; Perret, C.; Valdivieso, F.; Abarca, K.; Vial, P.
    Due to the recent yellow fever outbreak affecting the costal region of Brazil, including main touristic destinations, there is a high demand of yellow fever vaccination. This publication addresses the most relevant practical issues regarding this vaccine for tourists visiting Brazil and aims to serve as a guideline for non-expert physicians in Chile and elsewhere.